Pure tubular carcinoma of the breast: a case series.
Adjuvant treatment
Prognosis
Pure tubular breast carcinoma
Radiology
Surgery
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
16
02
2023
accepted:
25
04
2023
medline:
28
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Pure tubular breast carcinoma is a rare and well-differentiated tumor with high survival and low local recurrence rate. Our study aims to determine the clinical, radiological, appropriate management, and prognosis of this carcinoma. A review of Salah Azaiez institute registry from 2004 to 2019 was performed including seven cases of PTC of the breast. Clinical-pathologic features and outcomes were analyzed. The median follow-up was 3 years. In our study, we found that the cohort presented more frequently with pT1 disease and pN0 disease. Conservative surgery was more frequently indicated (five cases). All patients had hormone-receptor positivity and Human Epidermal growth factor Receptor 2 (HER2) negativity. The majority of tumors had a molecular profile luminal A and a low-grade SBR. In one case we found axillary lymph node metastasis. Adjuvant radiotherapy was indicated in all cases of breast conservation and in only one case of radical surgery. One patient received chemotherapy. The mean follow-up was 4 years. We did not find any local or distant recurrence in our study. PTC showed an excellent prognosis with a low SBR grade, a molecular profile luminal A, and a low incidence of recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Pure tubular breast carcinoma is a rare and well-differentiated tumor with high survival and low local recurrence rate. Our study aims to determine the clinical, radiological, appropriate management, and prognosis of this carcinoma.
MATERIALS AND METHODS
METHODS
A review of Salah Azaiez institute registry from 2004 to 2019 was performed including seven cases of PTC of the breast.
RESULTS
RESULTS
Clinical-pathologic features and outcomes were analyzed. The median follow-up was 3 years. In our study, we found that the cohort presented more frequently with pT1 disease and pN0 disease. Conservative surgery was more frequently indicated (five cases). All patients had hormone-receptor positivity and Human Epidermal growth factor Receptor 2 (HER2) negativity. The majority of tumors had a molecular profile luminal A and a low-grade SBR. In one case we found axillary lymph node metastasis. Adjuvant radiotherapy was indicated in all cases of breast conservation and in only one case of radical surgery. One patient received chemotherapy. The mean follow-up was 4 years. We did not find any local or distant recurrence in our study.
CONCLUSION
CONCLUSIONS
PTC showed an excellent prognosis with a low SBR grade, a molecular profile luminal A, and a low incidence of recurrence.
Identifiants
pubmed: 37365622
doi: 10.1186/s13256-023-03950-w
pii: 10.1186/s13256-023-03950-w
pmc: PMC10294325
doi:
Types de publication
Review
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
284Informations de copyright
© 2023. The Author(s).
Références
Medicine (Baltimore). 2021 Mar 19;100(11):e24977
pubmed: 33725968
Rep Pract Oncol Radiother. 2013 Sep 27;19(4):267-74
pubmed: 25061520
Radiat Oncol. 2018 Nov 20;13(1):226
pubmed: 30458816
J Breast Cancer. 2013 Dec;16(4):404-9
pubmed: 24454462
Anticancer Res. 2014 Jul;34(7):3647-56
pubmed: 24982382
Breast Dis. 2015;35(2):103-11
pubmed: 25567000
J Clin Oncol. 2010 Jan 1;28(1):99-104
pubmed: 19917872
Med Sci Monit. 2019 Jan 31;25:880-887
pubmed: 30700694
Korean J Radiol. 2007 Mar-Apr;8(2):103-10
pubmed: 17420627